Sara Michell Tolaney MD

Clinical Trials

• Bicalutamide in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2007 Mar 23

  Completed

  Phase 2

• Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer Start of enrollment: 2011 Jan 01

  Terminated

  Phase 1

• Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

  COMPLETED

  PHASE2

• Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer Start of enrollment: 2012 Mar 01

  Completed

  Phase 2

• A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01

  Completed

  Phase 1

• Cabozantinib for Metastatic Triple Negative BrCa Start of enrollment: 2013 Feb 01

  Completed

  Phase 2

• T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

  ACTIVE_NOT_RECRUITING

  PHASE2

• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17

  COMPLETED

  PHASE3

• Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer Start of enrollment: 2014 May 19

  Completed

  Phase 1

• A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10

  Completed

  Phase 2

• A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22

  ACTIVE_NOT_RECRUITING

  PHASE3

• Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Start of enrollment: 2016 Mar 09

  Completed

  Phase 1, Phase 2

• A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Start of enrollment: 2016 Nov 14

  ACTIVE_NOT_RECRUITING

  PHASE1

• Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer Start of enrollment: 2016 Aug 18

  ACTIVE_NOT_RECRUITING

  PHASE1

• Ribociclib (LEE011) Rollover Study for Continued Access Start of enrollment: 2016 Dec 15

  Recruiting

  Phase 2

• A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Start of enrollment: 2017 Feb 23

  ACTIVE_NOT_RECRUITING

  PHASE1

• CISPLATIN + AZD-1775 In Breast Cancer Start of enrollment: 2017 Jan 18

  Completed

  Phase 2

• A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 Start of enrollment: 2017 Feb 17

  COMPLETED

  PHASE1

• A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2017 Mar 22

  Completed

  Phase 2

• Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC Start of enrollment: 2017 May 22

  Terminated

  Phase 2

• A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer Start of enrollment: 2017 Nov 30

  Completed

  Phase 2

• Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer Start of enrollment: 2018 Jan 30

  ACTIVE_NOT_RECRUITING

  PHASE2

• Olaparib + Sapacitabine in BRCA Mutant Breast Cancer Start of enrollment: 2018 Oct 01

  ACTIVE_NOT_RECRUITING

  PHASE1

• NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer Start of enrollment: 2019 Mar 08

  ACTIVE_NOT_RECRUITING

  PHASE2

• Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Start of enrollment: 2020 Sep 23

  ACTIVE_NOT_RECRUITING

  PHASE2

• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Start of enrollment: 2020 Jul 20

  RECRUITING

  PHASE2

• ATEMPT 2.0: Adjuvant T-DM1 vs TH Start of enrollment: 2021 Jun 16

  RECRUITING

  PHASE2

• Join now to see all